184
The continuing asthma epidemic
Asher MI, et al.
Lancet
2006;368:733−43.
6–7 year age group
6–7 year age group
Asthma
2.0
1.5
1.0
0.5
0
–0.5
–1.0
–1.5
–2.0
Change per year (%)
0 5 10 15 20 25 30 35 40
Mean prevalence (%)
Increased prevalence
Little change
Decreased prevalence
Reduction in exacerbations
FEV
1
= forced expiratory volume in 1 second.
50%
over
52 weeks
over the
fixed-steroid phase
(Weeks 0–24)
34%
over the
adjustable-steroid phase
(Weeks 24–52)
63%
Omalizumab reduced exacerbations over 52 weeks
in children with
severe
allergic asthma
Omalizumab reduced exacerbations over
52 weeks regardless of baseline FEV
1
49%
FEV
1
<80% predicted
51%
FEV
1
≥80% predicted
1
Lanier B,
et al
.
J Allergy Clin Immunol
2009;124:1210–6
;
2
Kulus M,
et al
.
Curr Med Res Opin
2010;26:1285–93;
3
Milgrom H,
et al
.
Pediatrics
2001;108:e36;
4
Busse W,
et al
.
N Engl J Med
2011;364:1005–15
IA05-EU
2
Simposium
